convertase


Also found in: Encyclopedia.

convertase

 [kon-ver´tās]
an enzyme of the complement system that activates specific components of the system.

con·ver·tase

(kon'ver-tāz),
Proteases of complement that convert one component into another through enzymatic cleavage.
See: component of complement.

convertase

/con·ver·tase/ (kon-ver´tās) an enzyme of the complement system that activates specific components of the system.

convertase

(1) Classical complement pathway C3/C5 convertase, EC 3.4.21.43.
(2) Alternate complement pathway C3/C5 convertase, EC 3.4.21.47.

con·ver·tase

(kon-vĕr'tās)
Proteases of complement that convert one component into another.
See: component of complement

convertase

an enzyme that converts a substance to its active state.
References in periodicals archive ?
The PCSK9 gene was first identified by virtue of its homology to other genes of the protein convertase superfamily (1).
Furin is a ubiquitous proprotein convertase enriched in the trans-Golgi network and is well-conserved among mammals (20).
Subtilisin-like Proprotein Convertases (SPCs) are a family of eukaryotic endoproteases that function in the secretory pathway.
She has a mutant gene for prohormone convertase 1, an enzyme that activates certain proteins, including insulin, as the final step in their production.
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease.
evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).
TM) ](evolocumab), the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.
It is clear that these proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide a powerful therapy for reducing LDL cholesterol, with a reported decrease of about 60% after only 12 or 52 weeks of treatment.
This lack of consensus is further complicated by growing evidence that the current NT-proBNP immunoassays may detect blood proBNP in HF patients, which is caused by the lack of processing of the precursor proBNP by furin and corin protease convertase present in the circulation (6-8).
GP-C was posttranscriptionally processed by S1P (the cellular proprotein convertase site 1 protease) to yield the glycoproteins, and the consensus motif R-(R/K/ H)-L-(A/L/S/T/F) was identified as the S1P recognition site of Luna virus glycoprotein (11,12).
Partial Purification and Characterization of Secreted Proprotein Convertase Furin and PACE4.
When complement proteins are triggered into action by a microbe, the proteins ultimately form a complex enzyme called C3 convertase, which triggers a cascade of immune and inflammatory reactions.